Download Formulary Updates Volume 13, Issue 3 · March 2015

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Prescription costs wikipedia , lookup

Pharmacogenomics wikipedia , lookup

Pharmacognosy wikipedia , lookup

Pharmaceutical marketing wikipedia , lookup

Medication wikipedia , lookup

Specialty drugs in the United States wikipedia , lookup

Ciprofloxacin wikipedia , lookup

Ofloxacin wikipedia , lookup

Compounding wikipedia , lookup

340B Drug Pricing Program wikipedia , lookup

Adherence (medicine) wikipedia , lookup

Medical prescription wikipedia , lookup

Levofloxacin wikipedia , lookup

Pharmacist wikipedia , lookup

Pharmacy wikipedia , lookup

Electronic prescribing wikipedia , lookup

Transcript
Formulary Updates
Volume 13, Issue 3 · March 2015
Inside this issue: CareLink subsidy changes
1. Acetaminophen, dichloralphenazone, and isometheptene oral capsules (Midrin) - due to a substantial price increase, this medication is no longer subsidized. NSAIDs and triptans are formulary alternatives available for tension headaches and migraines. Or, prescribers may submit a non-formulary request
online.
2. Carbamazepine 100 mg extended release capsule (Carbatrol)– the 100 mg extended release capsule
was added to formulary. The 200 mg and 300 mg ER were already on formulary. Carbatrol is available
through a Medication Assistance Program (MAP) and CareLink will subsidize pending obtainment
through MAP.
3. Dapagliflozin 5 mg and 10 mg oral tablet (Farxiga) - a sodium glucose cotransporter 2 (SGLT2) inhibitor added to formulary for use according to the UHS Outpatient Glycemic Control Algorithm for Adults with
Type 2 Diabetes (available at: http://www.universityhealthsystem.com/clinical-pathways-and-guidelines/).
This medication is available for CareLink members through a BULK MAP, which allows same day
availability for eligible patients.
4. Levofloxacin (Levaquin)- all dosage forms were added to formulary and are subsidized. Levofloxacin will
replace moxifloxacin (Avelox) on formulary. Ciprofloxacin also remains on formulary and is subsidized.
The following medications were removed from the formulary and are no longer subsidized:
 Moxifloxacin (Avelox) - ciprofloxacin and levofloxacin are available alternatives.
UHS pharmacies participate in the 340B drug pricing program and must comply with program requirements.

CareLink members with prescriptions from UHS providers and locations can fill prescriptions at
any UHS pharmacy.

Members with prescriptions from outside primary care providers (e.g. CentroMed, Communicare, South Alamo Medical Group) will be referred to specific pharmacies for assistance.

Members with prescriptions from outside specialists (e.g. MARC clinics) must have referrals/
consults from a UHS provider in order for prescriptions to be filled at any UHS pharmacy. Otherwise, members will be referred to the RBGC Pharmacy for assistance.
For more information related to the 340B drug pricing program and its requirements, you may visit
http://www.hrsa.gov/opa/index.html
*More information regarding actions taken by the Pharmacy and Therapeutics (P&T) Committee is available on the UHS intranet by visiting Pharmacy
> Newsletters > P&T Action Memos. http://intranet/Services/Pharmacy/Pages/Newsletters.aspx
Complete UHS formulary information is available on the UHS intranet at: http://online.lexi.com/lco/action/home
CareLink non-formulary medication requests may be submitted at:
https://hr.universityhealthsystem.com/secure/formulary-request.shtml
Providers may also contact: Christine A. Gonzalez, PharmD, Manager, Pharmacy Programs-CareLink at
[email protected] or 358-3180
1